Smoking Relapse-Prevention Intervention for Cancer Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01630161 |
Recruitment Status :
Active, not recruiting
First Posted : June 28, 2012
Last Update Posted : October 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Smoking Cessation | Behavioral: Usual Care Behavioral: Smoking Relapse Prevention for Cancer Patients (SRP-CaP) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 441 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Smoking Relapse-Prevention Intervention for Cancer Patients |
Actual Study Start Date : | January 4, 2012 |
Actual Primary Completion Date : | May 15, 2015 |
Estimated Study Completion Date : | December 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Usual Care
Participants randomized to the Usual Care condition will receive standard care following recruitment.
|
Behavioral: Usual Care
Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion). |
Active Comparator: Relapse-Prevention Intervention
Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
|
Behavioral: Smoking Relapse Prevention for Cancer Patients (SRP-CaP)
The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One). |
- Number of Participants with Relapse at 6 Months [ Time Frame: 6 Months ]Number of participants with smoking relapse at 6 months follow-up for each treatment arm.
- Number of Participants with Relapse at 12 Months [ Time Frame: 12 Months ]Number of participants with smoking relapse at 12 months for each treatment arm.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Have smoked at least 10 cigarettes per day for at least one year prior to cancer diagnosis
- Able to read and write English
- Able to give informed consent
- Have quit smoking after receiving their cancer diagnosis
- Have not quit greater than 3 months prior
Exclusion Criteria:
- Individuals who have been abstinent for greater than 3 months are not included because they are less likely to relapse. A quit will be defined as self-reported no smoking for 24 hours. Individuals with metastatic disease will be excluded because participation in the study might be burdensome.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01630161
United States, Florida | |
H. Lee Moffitt Cancer Center and Research Institute | |
Tampa, Florida, United States, 33612 |
Principal Investigator: | Vani Simmons, Ph.D. | H. Lee Moffitt Cancer Center and Research Institute |
Responsible Party: | H. Lee Moffitt Cancer Center and Research Institute |
ClinicalTrials.gov Identifier: | NCT01630161 |
Other Study ID Numbers: |
MCC-16458 5R01CA154596-02 ( U.S. NIH Grant/Contract ) |
First Posted: | June 28, 2012 Key Record Dates |
Last Update Posted: | October 29, 2020 |
Last Verified: | October 2020 |
relapse prevention smoking habit Forever Free |
Recurrence Disease Attributes Pathologic Processes |